Howard Levine > Dechert LLP > Philadelphia, United States > Lawyer Profile

Dechert LLP
United States
Howard Levine photo

Work Department

Intellectual Property




Howard W. Levine focuses his practice on intellectual property litigation, advising on some of the most complex and valuable biotechnology and pharmaceutical litigation matters of the past 25 years. Mr. Levine has been at the forefront of legal development in these practice areas, including precedent concerning the written description requirement under 35 U.S.C. § 112.

Mr. Levine regularly conducts all aspects of pre-trial, trial, and post-trial proceedings, including appeals to the U.S. Court of Appeals for the Federal Circuit and the U.S. Supreme Court. He concentrates on patent litigation before the federal district courts and the U.S. Court of Appeals for the Federal Circuit. Mr. Levine also has extensive experience in cases arising from the filing of Abbreviated New Drug Applications (ANDA).

Mr. Levine represents clients from both the pharmaceutical and biotechnology industries on an array of technologies, ranging from the inhibition of NF-B to genetically engineered corn. Notably, he was involved in litigation regarding the first biotechnology product to be marketed, human insulin, between Eli Lilly, Genentech and the Regents of the University of California.

Some prominent products Mr. Levine has provided litigation counsel on include, Humulin®, Humatrope®, Zantac®, Paxil®, Evista®, Xigris®, Cymbalta®, Gemzar®, Differin®, Savella®, Bunavail® and Belbuca®. Most recently, he defended Allergan/Forest’s patent covering its Saphris® sublingual product, delivering the opening statements at two separate trials (one on infringement and one on validity) and taking key witnesses concerning the nonobviousness and infringement of Forest’s patent. He also argued the appeal before the Federal Circuit.


  • American Intellectual Property Law Association
  • New York Intellectual Property Law Association
  • District of Columbia Bar (Intellectual Property Section)


  • Georgetown University Law Center, J.D., 1993, cum laude
  • Duke University, B.A., 1990, cum laude

Lawyer Rankings

United States > Intellectual property > Patents: litigation (full coverage)

Dechert LLP‘s practice garners praise for being ‘technically sophisticated, smart, transparent, and ethical’. The group headed by Philadelphia’s Martin J Black , which is able to ‘identify strengths and weaknesses as cases mature’, regularly acting on the plaintiff’s side, has a particular strength in the life sciences sector with a dedicated Hatch-Waxman litigation team. The New York-based Katherine Helm has a focus on pharmaceutical and biotech patent litigation. In 2021 Howard Levine and Jennifer Swan joined from Finnegan, Henderson, Farabow, Garrett & Dunner LLP. Silicon Valley’s Nisha Patel left the firm for an in-house position.